Clinical Trials
12
Active:1
Completed:3
Trial Phases
2 Phases
Phase 2:3
Phase 3:7
Drug Approvals
25
NMPA:13
EMA:12
Drug Approvals
Laronidase concentrated solution for infusion
- Product Name
- 艾而赞
- Approval Number
- 国药准字SJ20200010
- Approval Date
- Nov 15, 2024
NMPA
Rabbit Anti-human Thymocyte Immunoglobulin
- Product Name
- 即复宁
- Approval Number
- 国药准字SJ20150035
- Approval Date
- Oct 8, 2024
NMPA
Rabbit Anti-human Thymocyte Immunoglobulin
- Product Name
- 即复宁
- Approval Number
- 国药准字SJ20150036
- Approval Date
- Oct 8, 2024
NMPA
Agalsidase Beta for Injection
- Product Name
- 法布赞
- Approval Number
- 国药准字SJ20190040
- Approval Date
- Jul 4, 2024
NMPA
Agalsidase Beta for Injection
- Product Name
- 法布赞
- Approval Number
- 国药准字SJ20190041
- Approval Date
- Apr 25, 2024
NMPA
Alglucosidase Alfa for Injection
- Product Name
- 美而赞
- Approval Number
- 国药准字SJ20150049
- Approval Date
- Jul 16, 2020
NMPA
Laronidase concentrated solution for infusion
- Product Name
- 艾而赞
- Approval Number
- S20200010
- Approval Date
- Jun 2, 2020
NMPA
Rabbit Anti-human Thymocyte Immunoglobulin
- Product Name
- 即复宁
- Approval Number
- S20150036
- Approval Date
- Apr 24, 2020
NMPA
- Prev
- 1
- 2
- Next
Clinical Trials
Distribution across different clinical trial phases (10 trials with phase data)• Click on a phase to view related trials
Phase 3
7 (70.0%)Phase 2
3 (30.0%)No trials found
News
No news found